These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 2885864)

  • 21. Electrodermal predictors of functional outcome and negative symptoms in schizophrenia.
    Schell AM; Dawson ME; Rissling A; Ventura J; Subotnik KL; Gitlin MJ; Nuechterlein KH
    Psychophysiology; 2005 Jul; 42(4):483-92. PubMed ID: 16008777
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neuroleptic prescription for Chinese schizophrenics in Hong Kong.
    Chiu H; Lee S; Leung CM; Wing YK
    Aust N Z J Psychiatry; 1992 Jun; 26(2):262-4. PubMed ID: 1353673
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Prediction of therapeutic success in acute neuroleptic treatment: results of an empirical study of 243 inpatient-treated schizophrenic patients].
    Möller HJ; Scharl W; von Zerssen D
    Fortschr Neurol Psychiatr; 1985 Oct; 53(10):370-83. PubMed ID: 2866152
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical characteristics of chronic schizophrenic patients presenting with severe anhedonia].
    Loas G; Noisette C; Legrand A; Boyer P; Delahousse J
    Encephale; 1996; 22(5):351-8. PubMed ID: 9035991
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prediction of "natural" course, relapse and prophylactic response in schizophrenic patients.
    Pietzcker A; Gaebel W
    Pharmacopsychiatria; 1983 Nov; 16(6):206-11. PubMed ID: 6141577
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clozapine maintenance therapy in schizophrenia.
    Gaszner P; Makkos Z
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 May; 28(3):465-9. PubMed ID: 15093952
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial.
    Ritsner MS; Gibel A; Ratner Y; Tsinovoy G; Strous RD
    J Clin Psychopharmacol; 2006 Oct; 26(5):495-9. PubMed ID: 16974191
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Auditory event-related potentials, auditory digit span, and clinical symptoms in chronic schizophrenic men on neuroleptic medication.
    Stefánsson SB; Jónsdóttir TJ
    Biol Psychiatry; 1996 Jul; 40(1):19-27. PubMed ID: 8780851
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lateral ventricular size, psychopathology, and medication response in the psychoses.
    Luchins DJ; Lewine RR; Meltzer HY
    Biol Psychiatry; 1984 Jan; 19(1):29-44. PubMed ID: 6142730
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Better prognosis due to new treatment approaches. Therapy of schizophrenia in 2002].
    Janssen B; Gaebel W
    MMW Fortschr Med; 2002 May; Suppl 2():72-6, 78. PubMed ID: 12070858
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [A critical study of the influence of negative symptoms on the therapeutic response in schizophrenia].
    Acuña MJ; Martín J; Noval D; Blanco M
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1998; 26(4):209-13. PubMed ID: 9807853
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antipsychotic efficacy of the antidepressant trimipramine: a randomized, double-blind comparison with the phenothiazine perazine.
    Bender S; Olbrich HM; Fischer W; Hornstein C; Schoene W; Falkai P; Haarmann C; Berger M; Gastpar M;
    Pharmacopsychiatry; 2003; 36(2):61-9. PubMed ID: 12734763
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Schizophrenic thinking and neuroleptic dosage.
    Puente AE; Andersson C
    J Clin Psychol; 1987 Mar; 43(2):189-97. PubMed ID: 2883201
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A study of the pharmacologic treatment of medication-compliant schizophrenics who relapse.
    Steingard S; Allen M; Schooler NR
    J Clin Psychiatry; 1994 Nov; 55(11):470-2. PubMed ID: 7989278
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Auditory evoked potentials as possible predictors of outcome in schizophrenic outpatients.
    Hegerl U; Gaebel W; Gutzman H; Ulrich G
    Int J Psychophysiol; 1988 Aug; 6(3):207-14. PubMed ID: 2900230
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcome and risks of ultra-long-term treatment with an oral neuroleptic drug. Relationship between perazine serum levels and clinical variables in schizophrenic outpatients.
    Pietzcker A; Poppenberg A; Schley J; Müller-Oerlinghausen B
    Arch Psychiatr Nervenkr (1970); 1981; 229(4):315-29. PubMed ID: 6111989
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An analysis of the skin conductance orienting response in samples of American, British, and German schizophrenics.
    Bernstein AS; Frith CD; Gruzelier JH; Patterson T; Straube E; Venables PH; Zahn TP
    Biol Psychol; 1982; 14(3-4):155-211. PubMed ID: 6127121
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Symptomatology and electrodermal activity as predictors of neuroleptic response in young male schizophrenic inpatients.
    Lindström EM; Ohlund LS; Lindström LH; Ohman A
    Psychiatry Res; 1992 May; 42(2):145-58. PubMed ID: 1352902
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased blink rates in schizophrenics. Influences of neuroleptics and psychopathology.
    Mackert A; Flechtner KM; Woyth C; Frick K
    Schizophr Res; 1991; 4(1):41-7. PubMed ID: 1672606
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiovascular autonomic reactivity in schizophrenics under neuroleptic treatment: A potential predictor of short-term outcome?
    Agelink MW; Malessa R; Kamcili E; Zeit T; Lemmer W; Bertling R; Klieser E
    Neuropsychobiology; 1998; 38(1):19-24. PubMed ID: 9701718
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.